Boston Scientific Corporation announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device. Key findings ...

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Travis Steed ...

Boston Scientific (NYSE:BSX) stock climbed 5% Monday after the medical device maker announced a study has shown its Watchman ...

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

The WATCHMAN FLX device showed superior safety with 8.5% major bleeding ... following a cardiac ablation were presented at ...

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

Boston Scientific Corp.’s OPTION study demonstrated left atrial appendage closure with the Watchman Flx device reduced risk of stroke compared to management with direct oral anticoagulants or warfarin ...